Skip to main content

Solence

Category: AI in Healthcare

A digital therapeutic app designed to provide personalized, lifestyle-based interventions for women with Polycystic Ovary Syndrome (PCOS). Solence was founded in 2022. The company is led by Clara Stephenson. Based in Strasbourg, France. Team size: 10-20. Total funding raised: €1.725 million (€1.6M Seed + €125K grant from Région Grand Est). Latest round: Seed. Key investors include Impact Shakers Ventures, Céline Lazorthes, Berthe Latreille, Stephane Mardel, BPI France.

Founded
2022
Headquarters
Strasbourg, France
Team size
10-20
Total funding
€1.725 million (€1.6M Seed + €125K grant from Région Grand Est)

Value proposition

To provide accessible, personalized, and science-backed non-pharmaceutical care for PCOS management by combining biomedical knowledge with habit-forming science.

Products and solutions

Solence Mobile App: Features a 12-week lifestyle intervention program, symptom tracking, personalized advice, and educational content.

Unique value

The company's approach is deeply rooted in the founder's personal experience with PCOS, leading to a patient-centric product. It focuses specifically on lifestyle and behavioral changes as a primary therapeutic method, distinguishing it from broader health trackers.

Target customer

Women diagnosed with or suspecting they have Polycystic Ovary Syndrome (PCOS).

Industries served

Healthcare, FemTech, Digital Therapeutics, Wellness Tech

Technology advantage

Leverages AI to create personalized care plans based on user data and symptom mapping. Its core IP lies in the proprietary content and structure of its 12-week digital therapeutic program, which is based on peer-reviewed research.

How they differentiate

Solence is a dedicated digital therapeutic specifically for PCOS, unlike Flo which is a general women's health tracker or Oova which focuses on hormone monitoring for fertility. It emphasizes a lifestyle-led program over pharmaceutical management and aims to complement, not replace, traditional medical care.

Main competitors

Flo Health, Oova Life, Allara Health

Key partnerships

BPI France, Besins Healthcare France (partnership since 2023 for PCOS supplements), CHU (University Hospital) pilot study with results expected end of 2025, Région Grand Est (€125K grant April 2026)

Notable customers

App is available in early access/beta; specific user numbers are not publicly disclosed.

Major milestones

Closed a €1.6 million seed round in July 2025 (finalized Feb 2025). Launched its digital therapeutic program for PCOS in an early access/beta phase. Successfully built a large, engaged community via the 'Les Natives' blog, validating the market need. Received €125,000 grant from Région Grand Est in April 2026. Partnership with Besins Healthcare France and CHU pilot study underway.

Growth metrics

The precursor to the company, a PCOS blog called 'Les Natives' founded by the CEO, grew to over 135,000 visits and 8,000 followers, demonstrating strong community engagement and a clear market need before the product was built.

Market positioning

A specialized, niche provider targeting the underserved market of PCOS patients with a science-backed, non-pharmaceutical digital solution.

Geographic focus

Primarily France, with plans for European expansion.

Patents and IP

Information on patents is not publicly available. The core IP is centered on the proprietary content, structure of its digital therapeutic program, and the AI-based personalization engine.

About Clara Stephenson

Clara Stephenson is the founder and CEO of Solence, a digital health company focused on Polycystic Ovary Syndrome (PCOS). Prior to founding Solence in 2022, she worked as a corporate lawyer at major firms like Ernst & Young and PwC. Her personal decade-long journey with a misdiagnosed case of PCOS inspired her to leave her legal career and create Solence. She also founded 'Les Natives,' the first French blog dedicated to raising awareness about PCOS. Her work with Solence combines her personal experience with a drive to innovate in women's healthcare, aiming to provide personalized, lifestyle-based interventions for a condition that affects millions of women worldwide.

Official website: